These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 37207144

  • 1. Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization.
    Lin LW, Ke K, Yan LY, Chen R, Huang JY.
    Front Oncol; 2023; 13():1178428. PubMed ID: 37207144
    [Abstract] [Full Text] [Related]

  • 2. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    Diao L, Wang C, You R, Leng B, Yu Z, Xu Q, Cheng Y, Yin G.
    J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
    [Abstract] [Full Text] [Related]

  • 3. Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas.
    Lin Z, Chen D, Hu X, Huang D, Chen Y, Zhang J, Li X, Zou X.
    Am J Cancer Res; 2023 Apr; 13(11):5455-5465. PubMed ID: 38058801
    [Abstract] [Full Text] [Related]

  • 4. Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study.
    Chen Y, Jia L, Li Y, Cui W, Wang J, Zhang C, Bian C, Wang Z, Lin D, Luo T.
    Ann Surg Oncol; 2024 Nov; 31(12):7860-7869. PubMed ID: 39090499
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lin LW, Yan LY, Ke K, Yang WZ, Lin JQ, Huang N.
    Brachytherapy; 2023 Nov; 22(6):858-871. PubMed ID: 37574351
    [Abstract] [Full Text] [Related]

  • 6. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
    An C, Fu Y, Li W, Zuo M, Wu P.
    Cancer; 2023 Jul 15; 129(14):2235-2244. PubMed ID: 37029486
    [Abstract] [Full Text] [Related]

  • 7. Hepatic Arterial Infusion Chemotherapy Combined Lenvatinib and PD-1 Inhibitor Showed Improved Survival for Infiltrative Hepatocellular Carcinoma: A Multicenter Cohort Study.
    Li R, Wang X, Li H, Wang M, Wang J, Wang W, Zhou Q.
    J Hepatocell Carcinoma; 2024 Jul 15; 11():1727-1740. PubMed ID: 39281003
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of HepaSphere Drug-Eluting Bead Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy as the Second-Line Treatment in Advanced Hepatocellular Carcinoma.
    Liu B, Gao S, Guo J, Kou F, Liu S, Zhang X, Feng A, Wang X, Cao G, Chen H, Liu P, Xu H, Gao Q, Yang R, Xu L, Zhu X.
    J Hepatocell Carcinoma; 2024 Jul 15; 11():477-488. PubMed ID: 38463543
    [Abstract] [Full Text] [Related]

  • 9. Addition of Immune Checkpoint Inhibitor Showed Better Efficacy for Infiltrative Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy and Lenvatinib: A Multicenter Retrospective Study.
    Wang W, Li R, Li H, Wang M, Wang J, Wang X, Zhou Q.
    Immunotargets Ther; 2024 Jul 15; 13():399-412. PubMed ID: 39184311
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.
    Wang J, Zhao M, Han G, Han X, Shi J, Mi L, Li N, Yin X, Duan X, Hou J, Yin F.
    Technol Cancer Res Treat; 2023 Jul 15; 22():15330338231166765. PubMed ID: 37161343
    [Abstract] [Full Text] [Related]

  • 12. Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study.
    Cai M, Liang L, Zhang J, Chen N, Huang W, Guo Y, Hong X, Lin L, Liu Y, Dan C, Deng H, Liu X, Zhou J, Chen Y, Chen H, Zhu K.
    Int J Surg; 2024 Jun 13; 110(12):7860-70. PubMed ID: 38869974
    [Abstract] [Full Text] [Related]

  • 13. Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience.
    Zhao W, Liu C, Wu Y, Yao Z, Dou Q, Li W, Zhao X, Xia N.
    Transl Cancer Res; 2024 May 31; 13(5):2315-2331. PubMed ID: 38881913
    [Abstract] [Full Text] [Related]

  • 14. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
    Yu B, Zhang N, Feng Y, Zhang Y, Zhang T, Wang L.
    J Hepatocell Carcinoma; 2023 May 31; 10():1735-1748. PubMed ID: 37822726
    [Abstract] [Full Text] [Related]

  • 15. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
    Fu S, Xu Y, Mao Y, He M, Chen Z, Huang S, Li D, Lv Y, Wu J.
    Cancer Med; 2024 May 31; 13(9):e7105. PubMed ID: 38686567
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: exploring the influence of prior transarterial chemoembolization and additional transarterial chemoembolization on survival outcomes.
    Hien PN, Chun HJ, Oh JS, Kim SH, Choi BG.
    J Gastrointest Oncol; 2024 Apr 30; 15(2):721-729. PubMed ID: 38756625
    [Abstract] [Full Text] [Related]

  • 19. Analysis on Efficacy of Hepatic Artery Infusion Chemotherapy with or without Lenvatinib for Unresectable Hepatocellular Carcinoma.
    Yuan W, Yue W, Wen H, Wang X, Wang Q.
    Eur Surg Res; 2023 Apr 30; 64(2):268-277. PubMed ID: 36812900
    [Abstract] [Full Text] [Related]

  • 20. HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study.
    Chang X, Li X, Sun P, Li Z, Sun P, Ning S.
    BMC Cancer; 2024 Apr 16; 24(1):480. PubMed ID: 38627684
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.